市場調查報告書
商品編碼
1466143
去腎神經設備市場:按技術、產品、疾病應用和最終用戶分類 - 全球預測 2024-2030Renal Denervation Devices Market by Technology (Micro-Infusion-Based, Pharmacologic Ablation, Radiofrequency-Based), Products (Catheters, Nerve Modifying Agents, RF Generator), Disease Application, End-User - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
腎臟去神經設備市場規模預計2023年為2.3629億美元,2024年達2.6644億美元,預計2030年將達到5.7985億美元,複合年成長率為13.68%。
去腎交感神經裝置是醫療設備。這些設備透過針對腎動脈周圍多餘的交感神經提供了另一種解決方案,腎動脈在調節血壓方面發揮關鍵作用,並有助於高血壓的發展。由於生活方式的改變,全球人群難治性高血壓的盛行率不斷增加,人們越來越意識到去腎神經術相對於傳統藥物治療的好處,以及老年人口的增加正在推動去腎神經術設備市場的成長。然而,去腎神經裝置、相關程序和一些嚴格的法律規範的高成本可能會阻礙市場成長。設備設計和技術方面的技術進步正在提高腎去神經術治療的功效和安全性,並有望創造利潤豐厚的市場機會。
主要市場統計 | |
---|---|
基準年[2023] | 2.3629億美元 |
預測年份 [2024] | 26644萬美元 |
預測年份 [2030] | 57985萬美元 |
複合年成長率(%) | 13.68% |
技術:基於超音波的腎臟去神經技術的採用率很高
基於微量輸注的腎去神經術涉及將少量抗高血壓藥物直接注入腎動脈周圍的空間。這種有針對性的方法可以最大限度地減少全身副作用並提高藥物療效。藥物消融使用神經毒性藥物(例如酒精或胍乙啶)以化學方式破壞過度活躍的腎臟神經。當由於解剖複雜性或禁忌症而無法採用射頻或超音波方法時,首選此手術。射頻腎去神經術涉及應用受控電能來破壞目標腎神經。該方法因其準確性、安全性和降低血壓的有效性而受到青睞。基於超音波的腎去神經術使用高頻聲波產生局部熱量來破壞過度活躍的腎神經。這種非侵入性方法對於有禁忌症或對其他方法過敏的患者很有吸引力。
產品多電極導管因其手術時間短而被廣泛使用。
導管是腎臟去神經手術中使用的主要設備,它提供射頻能源來消融或改變引起高血壓的神經。導管主要用於其微創性和針對特定神經的精確性。多電極導管的尖端有多個電極,可以同時消融多個神經部位,這可能會減少手術時間並提高療效。神經調節劑是與腎臟去神經裝置搭配使用的藥物,可改善手術結果。這些藥物可改善患者的整體反應或最大程度地減少手術中可能出現的併發症。 RF(射頻)產生器是腎臟去神經手術中使用的重要設備,可將受控能量傳遞到消融神經的導管。單電極導管的尖端有一個電極,用於順序消融神經部位。這些導管可以更精確地瞄準特定神經,但該過程可能比多電極導管花費更長的時間。
疾病應用:擴大去腎神經裝置在高血壓治療的應用
去腎神經裝置已成為糖尿病合併高血壓和腎臟病病患者的有效治療方法。去腎神經裝置可抑制交感神經的過度活躍,進而加劇糖尿病併發症。在心臟衰竭患者中,交感神經活動增加,導致血壓升高和體液超負荷,這是腎臟損傷進展的因素。去腎神經治療可以有效抑制這些患者的交感神經亢進,改善心臟功能和整體生活品質。在高血壓中,去腎神經支配透過損害腎交感神經並減少其對血壓調節的影響來幫助降低血壓。去腎神經裝置被認為是慢性腎臟病(CKD)患者的潛在治療選擇,這些患者經常患有高血壓和糖尿病併發症。這種調節交感神經系統的治療方法可能有助於減緩 CKD 的進展並減輕與腎功能障礙相關的症狀。
最終用戶:門診醫療中心偏好去腎神經裝置作為微創且經濟高效的解決方案
門診護理中心 (ACC) 是一家門診設施,提供各種醫療服務,包括腎臟相關疾病的診斷和治療,並為高血壓患者的管理提供去腎神經裝置。 ACC 青睞微創、經濟高效的解決方案,以確保患者的安全和舒適,同時最大限度地提高業務效率。診斷中心和醫院對於透過早期發現和介入來控制高血壓至關重要。隨著全球範圍內不受控制的高血壓和抗藥性病例的增加,這些設施需要先進的去腎神經設備來最佳化患者的治療效果。醫院在選擇去腎神經裝置時優先考慮易用性、對現有設備的適應性以及強大的臨床資料支援。研究機構和學術中心處於高血壓治療的最前沿,開發腎臟去神經術的新治療方法和設備。這些組織專注於具有強力臨床證據的最尖端科技,以支持該領域的未來發展。
區域洞察
市場狀況很重要,因為美洲人口中高血壓盛行率很高,並且在新治療方法的研究上投入了大量資金。技術的進步和醫療保健專業人員對創新治療方法的認知不斷提高正在推動對這些設備的需求。由於各國對去腎神經療法的認知不斷提高以及有利的報銷政策,歐盟顯示出巨大的市場成長潛力。高血壓預防和管理方面的合作正在加速該領域的研究和開發舉措。由於高血壓盛行率不斷上升,加上生活方式的改變和都市化,中東和非洲地區是去腎神經裝置的一個前景廣闊的市場。在亞太地區,由於政府對高血壓研究的資助和舉措,臨床試驗和專利申請的數量正在增加。強大的醫療基礎設施、對技術進步的濃厚興趣、高血壓管理意識的提高以及醫療設施的改善正在促進該地區去腎神經設備市場的成長。
FPNV定位矩陣
FPNV定位矩陣對於評估去腎神經裝置市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標,以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估,供應商被分為四個成功程度不同的像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可以對腎去神經設備市場供應商的現狀進行深入而詳細的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻,以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外,該分析還提供了對該行業競爭特徵的寶貴見解,包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略,從而在市場上獲得競爭優勢。
1. 市場滲透率:提供有關主要企業所服務的市場的全面資訊。
2. 市場開拓:我們深入研究利潤豐厚的新興市場,並分析其在成熟細分市場的滲透率。
3. 市場多元化:提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。
4.競爭力評估與資訊:對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。
5. 產品開發與創新:提供對未來技術、研發活動和突破性產品開發的見解。
1.去腎神經裝置市場的市場規模和預測是多少?
2.在腎臟去神經設備市場預測期內,有哪些產品、細分市場、應用和領域需要考慮投資?
3.去腎神經器材市場的技術趨勢和法規結構是什麼?
4.去腎神經設備市場主要供應商的市場佔有率是多少?
5. 進入去腎神經器材市場的合適型態和策略手段是什麼?
[192 Pages Report] The Renal Denervation Devices Market size was estimated at USD 236.29 million in 2023 and expected to reach USD 266.44 million in 2024, at a CAGR 13.68% to reach USD 579.85 million by 2030.
Renal denervation devices are medical tools that provide minimally invasive therapy for patients suffering from drug-resistant hypertension or high blood pressure that do not respond adequately to conventional pharmacological therapies. These devices offer an alternative solution by targeting the overactive sympathetic nerves surrounding the renal arteries, which play a crucial role in regulating blood pressure and contribute to the development of hypertension. The increasing prevalence of resistant hypertension among the global population due to lifestyle changes, rising awareness about the benefits of renal denervation procedures over conventional drug therapies, and the growing geriatric population are driving the renal denervation devices market growth. However, the high cost of renal denervation devices, associated procedures, and several stringent regulatory frameworks may hamper market growth. Technological advancements in device design and procedural techniques have improved efficacy and safety profiles for renal denervation treatments, which is expected to create a lucrative market opportunity.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 236.29 million |
Estimated Year [2024] | USD 266.44 million |
Forecast Year [2030] | USD 579.85 million |
CAGR (%) | 13.68% |
Technology: High adoption of ultrasound-based renal denervation technology
Micro-infusion-based renal denervation involves delivering small doses of anti-hypertensive drugs directly into the periarterial space surrounding the renal arteries. This targeted approach minimizes systemic side effects and improves drug efficacy. Pharmacologic ablation involves chemically destroying overactive renal nerves using neurotoxic agents such as alcohol or guanethidine. This technique is preferred when radiofrequency or ultrasound-based approaches are not feasible due to anatomical complexities or contraindications. Radiofrequency-based renal denervation involves applying controlled electrical energy to destroy targeted renal nerves. This method is preferred for its precision, safety, and effectiveness in reducing blood pressure. Ultrasound-based renal denervation uses high-frequency sound waves to generate localized heat that disrupts overactive renal nerves. This non-invasive technique makes it attractive for patients with contraindications or sensitivities to other methods.
Product: Significant use of multi-electrode catheters for their shorter-time of procedures
Catheters are the primary device used in renal denervation procedures to deliver radiofrequency energy to ablate or modify nerves responsible for hypertension. They are primarily used for their minimally invasive nature and precision in targeting specific nerves. Multi-electrode catheters have multiple electrodes on the tip that enable simultaneous ablation of multiple nerve sites, reducing procedure time and potentially increasing efficacy. Nerve-modifying agents are pharmaceuticals that work alongside renal denervation devices to enhance procedural outcomes. These agents may improve overall patient response or minimize potential complications arising from the procedure. An RF (Radiofrequency) generator is an essential device used in renal denervation procedures for providing controlled energy to catheters to ablate nerves. Single electrode catheters feature a single electrode at the tip and are used for sequential ablation of nerve sites. These catheters offer greater precision in targeting specific nerves but may require longer procedures than multi-electrode variants.
Disease Application: Proliferating use of renal denervation devices for treating hypertension
Renal denervation devices have emerged as an effective treatment for diabetic patients suffering from hypertension and nephropathy. These devices modulate the overactive sympathetic nervous system responsible for worsening diabetic complications. Heart failure patients experience high sympathetic activity, leading to increased blood pressure and fluid overload factors contributing to progressive kidney damage. Renal denervation therapy can effectively reduce sympathetic hyperactivity in these patients, improving cardiac function and overall quality of life. In hypertension, renal denervation helps lower blood pressure by disrupting the renal sympathetic nerves, reducing their influence on blood pressure regulation. Renal denervation devices are being explored as a potential treatment option for chronic kidney disease (CKD) patients who often suffer from hypertension and diabetic complications. The therapy's ability to modulate the sympathetic nervous system may help slow CKD progression and alleviate symptoms associated with kidney dysfunction.
End-User: Ambulatory care centers prioritize renal denervation devices as a minimally invasive and cost-effective solution
Ambulatory care centers (ACCs) are outpatient facilities that provide various medical services, including diagnosis and treatment for kidney-related diseases, and offer renal denervation devices to manage patients with hypertension. ACCs prefer minimally invasive and cost-effective solutions to ensure patient safety and comfort while maximizing operational efficiency. Diagnostic centers and hospitals are crucial in managing hypertension through early detection and intervention. With a growing global prevalence of uncontrolled hypertension and drug-resistant cases, these institutions require advanced renal denervation devices for optimal patient outcomes. Hospitals prioritize ease of use, adaptability with existing equipment, and robust clinical data support when selecting renal denervation devices. Research institutions and academic centers are at the forefront of hypertension management, developing novel therapies and devices for renal denervation. These organizations focus on cutting-edge technology with strong clinical evidence to support future advancements in the field.
Regional Insights
The Americas has a significant landscape in the renal denervation devices market due to a high prevalence of hypertension among its population and substantial investments in research for novel therapies. Advancements in technology and growing awareness about innovative treatment options amongst healthcare professionals have fueled demand for these devices. The EU shows significant potential for market growth owing to increased awareness about renal denervation therapy and favorable reimbursement policies across countries. Collaborative efforts on hypertension prevention and control have accelerated R&D initiatives in this domain. The MEA region holds promising opportunities for renal denervation devices due to a rising incidence of hypertension coupled with lifestyle changes and urbanization. In the APAC region, government funding and initiatives for hypertension research resulted in a growing number of clinical trials and patent filings. Robust healthcare infrastructure, a strong focus on technological advancements, increased awareness about hypertension management, and improved healthcare facilities have contributed to the region's renal denervation devices market growth.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Renal Denervation Devices Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Renal Denervation Devices Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Renal Denervation Devices Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Ablative Solutions, Inc., AngioDynamics, Inc., Aria CV, Inc., AtriCure, Inc., Bio-Heart, Boston Scientific Corporation, Cardinal Health, Inc., Kalos Medical, Medtronic PLC, Mercator MedSystems, Inc., Otsuka Holdings Co., Ltd., Shanghai Meiliweiye Medical Technology Co., Ltd., SoniVie, Symap Medical, Ltd., Symple Surgical, Inc., and Terumo Corporation.
Market Segmentation & Coverage
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
1. What is the market size and forecast of the Renal Denervation Devices Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Renal Denervation Devices Market?
3. What are the technology trends and regulatory frameworks in the Renal Denervation Devices Market?
4. What is the market share of the leading vendors in the Renal Denervation Devices Market?
5. Which modes and strategic moves are suitable for entering the Renal Denervation Devices Market?